<DOC>
	<DOCNO>NCT00017355</DOCNO>
	<brief_summary>RATIONALE : Vaccines make patient 's white blood cell mixed tumor antigen may make body build immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness vaccine therapy treat patient metastatic melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety tolerability antigen-pulsed dendritic cell vaccine patient metastatic melanoma . - Determine longevity melanoma-specific immunity patient treated regimen . - Perform serial analysis T-cell B-cell function patient treat regimen . OUTLINE : Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily day 1-6 1-7 . Patients undergo apheresis day 6 7 6-8 obtain peripheral blood mononuclear cell ( PBMC ) . PBMC process CD34+ cell isolation . These autologous CD34+ hematopoietic progenitor cell culture generate dendritic cell ( DC ) . DC pulse endotoxin-free keyhole limpet hemocyanin HLA-A2-01 restrict flu-matrix peptide derive melanoma-associated tumor antigen ( MART-1:27-35 , gp100:209-217 , MAGE-3 ) . Antigen-pulsed DC incubate interferon alfa induce DC maturation . Patients receive prim injection antigen-pulsed DC vaccine SC every 2 week 8 week . Treatment repeat 2 , 3 , 4 , 5 month last priming injection absence unacceptable toxicity disease progression . Patients follow 2 4 week every 3 month 1.5 year . PROJECTED ACCRUAL : A total 18 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic melanoma HLAA201 phenotype Measurable disease No active CNS hepatic metastasis PATIENT CHARACTERISTICS : Age : 21 Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : See Disease Characteristics No viral hepatitis Renal : Not specify Cardiovascular : No prior venous thrombosis , angina pectoris , congestive heart failure Lactate dehydrogenase less 2 time normal Pulmonary : No prior asthma Immunologic : Intradermal skin test positivity mumps , Candida , streptokinase antigen No known sensitivity E. coli drug preparation No prior allergy influenza vaccine No active infection No prior autoimmune disease ( e.g. , lupus erythematosus , rheumatoid arthritis , thyroiditis ) Other : HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 8 week since prior interleukin2 At least 4 week since prior interferon alfa Chemotherapy : At least 8 week since prior chemotherapy Endocrine therapy : At least 2 week since prior corticosteroid No concurrent corticosteroid Radiotherapy : Not specify Surgery : Not specify Other : No concurrent immunosuppressive agent At least 2 week since prior immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>